Accelerating growth under the Medium-Term Management Plan “MODE 2017”
First written in FY2016. 3 of 7 entries say "Reframed", first in FY2020. Latest entry: 2026-09-25.
No other company in this theme has enough history to compare yet.
- 2026-09-25AdvancedChanges in Officers
「To respond to changes in the business environment and achieve sustainable growth and strengthen our earnings base, we are developing an organizational structure capable of steadily implementing structural reforms to our earnings model. We are making this organizational change to clarify the respective roles of the corporate planning and FP&A functions, improve the quality and speed of management decisions, and strengthen execution capabilities by reorganizing the business development function.」
The establishment of an FP&A Department and the transfer of the Business Development Office gave concrete form to the structure for planning and control, management decision-making and execution in pursuit of sustainable growth and a stronger earnings base. - FY2026ReframedAnnual report
「Consolidated performance targets Fiscal year ending March 2027 Fiscal year ending March 2028 Fiscal year ending March 2029 Forecast Percentage Target Percentage Target Percentage Net sales (¥ million) 25,370 100.0% 27,500 100.0% 30,000 100.0% Operating profit (¥ million) 430 1.7% 1,000 3.6% 1,500 5.0% Net income attributable to owners of the parent (Note 1) (¥ million) 60 0.2% 500 1.8% 1,000 3.3%」
In addition to the framework of the previous long-term VISION “RT500,” annual targets for net sales, operating profit and net income attributable to owners of the parent from the fiscal year ending March 2027 through the fiscal year ending March 2029 are presented, making execution monitoring more specific on an annual basis. - 2026-05-13AdvancedEarnings presentation
「We position the fiscal year ending March 2027 as a turning point toward improved profitability. Through renewed sales growth driven by the introduction of new products and recovery in case volumes in the United States, as well as lower manufacturing costs and more efficient selling, general and administrative expenses, we aim to improve profitability toward the fiscal year ending March 2029.」
A rolling plan through the fiscal year ending March 2029 and an execution policy for improving profitability were given concrete form under the long-term VISION RT500. - FY2024ReframedAnnual report
「The company formulated the long-term VISION “RT500,” with the fiscal year ending March 2033 as its final year, and established the long-term management policy of “identifying the needs of medical professionals and providing services that contribute to improving treatment value to the medical front line in a timely and stable manner, with a high level of expertise and quality.” Its quantitative targets are consolidated net sales of at least ¥50 billion, an operating margin of at least 15%, ROE of at least 10% and a payout ratio of at least 30%, with the aim of increasing corporate value.」
The planning framework has been restructured from MODE2020 and MODE2023 to the long-term VISION “RT500,” with the fiscal year ending March 2033 as its final year. Long-term targets for net sales, profit margin, ROE and the payout ratio are specified. - FY2020ReframedAnnual report
「The company formulated the medium-term management plan “MODE2020,” covering the 3 years from the fiscal year ending March 2019 (the 47th fiscal year) to the fiscal year ending March 2021 (the 49th fiscal year). “MODE2020” sets out the medium-term management policy of “strengthening profitability in organic growth areas, establishing a foundation in strategic growth areas, strengthening the structure for executing strategy, and achieving sustainable, profitable growth over the medium to long term.”」
The medium-term plan has been changed from the previous “MODE2017” to “MODE2020,” covering the fiscal year ending March 2019 through the fiscal year ending March 2021, and has been restructured to focus on profitability, strategic growth areas and the strategy execution structure. - FY2017RestatedAnnual report
「The company formulated the medium-term management plan “MODE2017—Step up to the next stage—,” covering the 3 years from the fiscal year ending March 2016 (the 44th fiscal year) to the fiscal year ending March 2018 (the 46th fiscal year). Its medium-term management guideline is “accelerate growth into a new stage through proactive investment in growth areas.”」
The plan period, name and medium-term management guideline have been presented again unchanged from the previous fiscal year. - FY2016First statedAnnual report
「To address these various challenges, under the corporate philosophy of “contributing to healthcare through the development and sale of outstanding cutting-edge medical devices,” the company formulated the medium-term management plan “MODE2017—Step up to the next stage—,” covering the 3 years from the fiscal year ending March 2016 (the 44th fiscal year) to the fiscal year ending March 2018 (the 46th fiscal year). Its medium-term management guideline is “accelerate growth into a new stage through proactive investment in growth areas.”」
It was established as a 3-year plan covering the fiscal year ending March 2016 through the fiscal year ending March 2018.